drugset / Trial / NCT04807517

Buspirone Treatment of Anxiety in Williams Syndrome

NCT04807517

Phase 4 Completed 20 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to do a preliminary assessment of whether buspirone is effective, safe, and tolerable in the treatment of anxiety in children, adolescents, and adults with Williams syndrome.

Timeline

Start
2021-08-01
Primary completion
2023-09-11
Completion
2023-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Buspirone Small molecule 2.5 mg Oral